Climb Bio Inc (CLYM)

Apr 1, 2025, 7:00 AM EDT - 24 days ago

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Mar 27, 2025, 7:00 AM EDT - 4 weeks ago

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 4:05 PM EDT - 4 weeks ago

Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

Feb 25, 2025, 7:00 AM EST - 2 months ago

Climb Bio to Present at Upcoming Investor Conferences

Feb 24, 2025, 7:00 AM EST - 2 months ago

Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

Feb 4, 2025, 7:00 AM EST - 2 months ago

Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 9, 2025, 7:00 AM EST - 3 months ago

Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

Dec 19, 2024, 7:00 AM EST - 4 months ago

Climb Bio to be Added to the Nasdaq Biotechnology Index

Nov 12, 2024, 4:05 PM EST - 5 months ago

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 11, 2024, 7:00 AM EST - 5 months ago

Climb Bio Appoints Douglas E. Williams, Ph.D.

Oct 15, 2024, 7:00 AM EDT - 6 months ago

Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event

Oct 11, 2024, 12:30 PM EDT - 7 months ago

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

Oct 4, 2024, 7:00 AM EDT - 7 months ago

Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19

Oct 3, 2024, 10:00 AM EDT - 7 months ago

Climb Bio to Host Virtual Investor Event on October 15, 2024

Oct 2, 2024, 9:00 AM EDT - 7 months ago

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Sep 11, 2024, 7:00 AM EDT - 8 months ago

Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Aug 26, 2024, 7:00 AM EDT - 8 months ago

Eliem Therapeutics Announces Additions to its Leadership Team

Aug 14, 2024, 6:05 AM EDT - 9 months ago

Eliem Therapeutics Reports Second Quarter Financial Results

Jun 28, 2024, 1:58 PM EDT - 10 months ago

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Jun 28, 2024, 7:00 AM EDT - 10 months ago

Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Jun 27, 2024, 4:01 PM EDT - 10 months ago

Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement

Jul 20, 2023, 6:57 AM EDT - 1 year ago

Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself

Jul 20, 2023, 6:45 AM EDT - 1 year ago

Eliem Therapeutics Announces Plans to Explore Strategic Alternatives

May 11, 2023, 4:10 PM EDT - 2 years ago

Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights

Mar 6, 2023, 4:10 PM EST - 2 years ago

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Feb 9, 2023, 4:01 PM EST - 2 years ago

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Nov 30, 2022, 7:00 AM EST - 2 years ago

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

Nov 14, 2022, 6:10 AM EST - 2 years ago

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Nov 8, 2022, 7:00 AM EST - 2 years ago

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

Oct 5, 2022, 7:00 AM EDT - 2 years ago

Eliem Therapeutics Provides Update on Pipeline Progress

Aug 15, 2022, 6:10 AM EDT - 2 years ago

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Aug 2, 2022, 9:33 AM EDT - 2 years ago

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Aug 2, 2022, 7:00 AM EDT - 2 years ago

Eliem Therapeutics Provides ETX-810 Program Update

Jul 18, 2022, 7:00 AM EDT - 3 years ago

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Jul 7, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

Jun 27, 2022, 4:01 PM EDT - 3 years ago

Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)

Jun 21, 2022, 12:01 PM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More

TXMD WEBR

Jun 13, 2022, 10:49 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard

TXMD BEEM

May 16, 2022, 11:38 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated

CWH VERU

May 16, 2022, 6:10 AM EDT - 3 years ago

Eliem Therapeutics Reports First Quarter Financial and Business Highlights

Apr 25, 2022, 1:45 PM EDT - 3 years ago

Eliem Therapeutics shares sink more than 50% after lead program fails to show benefit in clinic

Apr 25, 2022, 9:06 AM EDT - 3 years ago

See Here Why Recently Listed Eliem Therapeutics Shares Are Plummeting

Apr 25, 2022, 7:00 AM EDT - 3 years ago

Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs

Apr 5, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

Mar 21, 2022, 7:00 AM EDT - 3 years ago

Eliem Therapeutics to Present at Stifel's 2022 CNS Days